NYMAX™ BIO BIO-BASED POLYAMIDE SOLUTIONS PROCESSING GUIDE 1 NYMAX BIO Formulated in glass fiber-filled or unfilled materials, Nymax™ BIO formulations utilize between 16 and 47 percent natural filler from renewable plant-based raw materials, reducing the carbon footprint value significantly at the beginning of the product lifecycle.

Each of such adjustments has not yet occurred, are out of the Company's control and/or cannot be reasonably predicted. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi e n t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

Each of such adjustments has not yet occurred, are out of the Company's control and/or cannot be reasonably predicted. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi e n t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

Each of such adjustments has not yet occurred, are out of the Company's control and/or cannot be reasonably predicted. These investments also consider our global footprint, and we are positioned very well and strategically from a regional perspective. 12 Growth Drivers 2020 Revenue ($ Millions) Long-Term Growth Rate Sustainable Solutions $ 560 8–12% Healthcare 555 8–10% Composites / 5G 212 10% Growth in Emerging Regions 672 5% Other (GDP growth) 1,784 2–3% Pro Forma Avient $ 3,783 6.5% Q 1 2 0 2 1 P E R F O R M A N C E U P D AT E $86 $123 2020PF 2021 $0.53 $0.89 2020PF 2021 Q1 2021 – ORGANIC PERFORMANCE ( T O TA L C O M PA N Y ) 14 Sales Adjusted Operating Income $991 $1,162 2020PF 2021 + 17% Adjusted EPS + 43% + 68% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Q1 2021 SEGMENT PERFORMANCE 15 CAI $536 $609 Sales ($ in millions) SEM Distribution $64 $89 Operating Income (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition +14% +39% $290 $363 Sales $19 $24 Operating Income +25% +26% (1) $185 $217 Sales $22 $34 Operating Income +17% +55% SPECIALTY EBITDA MARGIN EXPANSION 16 CAI (1) 2018-2020 financial information is pro forma to include a full year of Clariant Masterbatch business acquisition 15.3% 15.2% 16.2% 19.1% 2018 2019 2020 Q1 2021 14.8% 15.2% 17.6% 19.4% 2018 2019 2020 Q1 2021 (1) SEM • Continued portfolio transformation to high-growth end markets and sustainable solutions • Clariant Masterbatch synergy realization • Investments in composites and outdoor high performance applications drive growth and mix improvements CAI EBITDA MARGIN EXPANSION 17 Legacy CAI 18.9% 18.9% 21.0% 2019 2020 Q1 2021 Legacy Clariant MB 11.9% 13.8% 17.4% 2019 2020 Q1 2021 • Early synergy capture translating to the bottom line • Positive mix with growth in healthcare, consumer and packaging end-markets • World-class vitality index of 36% represents sales from products introduced in the last five years.

It is the responsibility of each person at Avient to ensure that all operations in the company are carried out in accordance with this policy.

It is the responsibility of each person at Avient to ensure that all operations in the company are carried out in accordance with this policy.

It is the responsibility of each person at Avient to ensure that all operations in the company are carried out in accordance with this policy.

While all due care and skill was exercised in carrying out this assessment, SAI Global accepts responsibility only for proven negligence.

MSC Certificate Place and date: For the issuing office: Shanghai, 20 March 2024 DNV - Business Assurance Building 9, No. 1591 Hongqiao Road, Changning DistrictShanghai China 200336 Zhu Hai Ming Management Representative Lack of fulfilment of conditions as set out in the Certification Agreement may render this Certificate invalid.

MSC Certificate Place and date: For the issuing office: Høvik, 23 January 2025 DNV Product Assurance AS Veritasveien 1, 1363 Høvik, Norway Cecilie Gudesen Torp Management Representative Lack of fulfilment of conditions as set out in the Certification Agreement may render this Certificate invalid.